Skip to content
Case

ESG-focused growth investor ECBF set to invest in the sustainable Danish Bioeconomy

The European Circular Bioeconomy Fund (ECBF) aims to contribute to achieving the European Green Deal goal of making Europe climate neutral by 2050. By investing in bio-based companies such as Biosyntia, ECBF recognizes the potential of Danish companies to contribute the transition towards a sustainable future.  

The European Circular Bioeconomy Fund (ECBF) aims to catalyze the transition towards a sustainable future by investing in biobased companies with high potential for innovation, favorable returns, and sustainable impact. Denmark has proven to be an attractive entrepreneurial ecosystem for the growth-stage venture capital fund and other experienced investors. The newest addition to the Fund’s portfolio is the Copenhagen-based Biosyntia. With the investment, ECBF joins Novo Seeds and Sofinnova Partners in the shareholder structure, as a leading investor in Biosyntia’s funding round of 11.5M EUR.

Biosyntia produces natural ingredients based on microbial fermentation processes. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes allowing the company to deliver natural ingredients at scale both affordably and sustainably. All products are natural, vegan and EU-sourced. Biosyntia already has commercial partnerships, including collaborations with large market players such as Givaudan and WACKER. The first product to be marketed is a bio-based biotin (vitamin B7) that can be used in food supplements, food and beauty products.

Biosyntia produces natural ingredients based on microbial fermentation processes. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes allowing the company to deliver natural ingredients at scale both affordably and sustainably. All products are natural, vegan and EU-sourced. Biosyntia already has commercial partnerships, including collaborations with large market players such as Givaudan and WACKER. The first product to be marketed is a bio-based biotin (vitamin B7) that can be used in food supplements, food and beauty products.

quote ikon
“Biosyntia is an impressive case of a sustainable change with a sound commercial basis. More and more companies are following this path thanks to the great scientific base in Denmark – especially within the field of bioeconomy. Denmark´s economic and academic system has been developed in various places, especially in Copenhagen and Aarhus, resulting in attractive innovations and companies for investors.” 
Michael Nettersheim General Partner, ECBF

How Invest in Denmark can support venture capital firms

Denmark is a fertile ground for promising start-ups within the bioeconomy sector and beyond. Nowadays, many promising start-ups aim to make the world more sustainable in different ways. Invest in Denmark helps international VCs navigate the environment by informing about relevant events, networks and conducting fact-finding missions in Denmark, just as we did for ECBF. We also support VC’s existing portfolio of companies who see potential for expansion to Denmark. 

Get in touch Want to learn more about the bio-solution scene & VC opportunities in Denmark?

We provide free-of-charge confidential and tailor-made solutions for foreign companies looking to set up a new business in Denmark or expand an existing one. Please contact one of our experts here: 

Loading...